Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Müller-Bohn

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Medizinische Monatsschrift Fur Pharmazeuten|November 30, 2004
[What is a cost benefit analysis?]Thomas Müller-Bohn
Medizinische Monatsschrift Fur Pharmazeuten|November 6, 2004
[What is a cost-benefit analysis?]Thomas Müller-Bohn
Medizinische Monatsschrift Fur Pharmazeuten|October 20, 2004
[What is a cost-effectiveness analysis?]Thomas Müller-Bohn
Deutsche Medizinische Wochenschrift (1946)|March 23, 2017
[Analysis of Secondary Data to Determine the Prevalence of Cardiovascular High Risk Patients with Hypercholesterolemia and Refractory Course of Treatment]Franz-Werner Dippel, Klaus G Parhofer, Thomas Müller-Bohn, et al.
Biomedical Instrumentation & Technology|April 10, 2002
Engineering and governmental challenge: 7-day/24-hour chronobiologic blood pressure and heart rate screening: Part IFranz Halberg, Germaine Cornélissen, Dan Wall, et al.
Biomedical Instrumentation & Technology|June 11, 2002
Engineering and governmental challenge: 7-day/24-hour chronobiologic blood pressure and heart rate screening: Part IIFranz Halberg, Germaine Cornélissen, Dan Wall, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Medizinische Monatsschrift Fur Pharmazeuten|November 30, 2004
[What is a cost benefit analysis?]Thomas Müller-Bohn
Medizinische Monatsschrift Fur Pharmazeuten|November 6, 2004
[What is a cost-benefit analysis?]Thomas Müller-Bohn
Medizinische Monatsschrift Fur Pharmazeuten|October 20, 2004
[What is a cost-effectiveness analysis?]Thomas Müller-Bohn
Deutsche Medizinische Wochenschrift (1946)|March 23, 2017
[Analysis of Secondary Data to Determine the Prevalence of Cardiovascular High Risk Patients with Hypercholesterolemia and Refractory Course of Treatment]Franz-Werner Dippel, Klaus G Parhofer, Thomas Müller-Bohn, et al.
Biomedical Instrumentation & Technology|April 10, 2002
Engineering and governmental challenge: 7-day/24-hour chronobiologic blood pressure and heart rate screening: Part IFranz Halberg, Germaine Cornélissen, Dan Wall, et al.
Biomedical Instrumentation & Technology|June 11, 2002
Engineering and governmental challenge: 7-day/24-hour chronobiologic blood pressure and heart rate screening: Part IIFranz Halberg, Germaine Cornélissen, Dan Wall, et al.
Pageof 1